NVCR

NovoCure Limited

15.60 USD
-0.02 (-0.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

NovoCure Limited stock is up 10.17% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 CALLs, 6 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Jan 16:27 17 Jan, 2025 10.00 CALL 60 138
18 Jan 18:38 17 Jan, 2025 10.00 PUT 460 2537
18 Jan 18:42 17 Jan, 2025 15.00 CALL 768 2699
19 Jan 14:32 16 Feb, 2024 17.50 PUT 100 5
19 Jan 14:37 16 Feb, 2024 17.50 PUT 130 5
19 Jan 20:55 16 Feb, 2024 17.50 PUT 300 5
25 Jan 17:17 17 Jan, 2025 10.00 CALL 50 125
29 Jan 16:20 17 May, 2024 15.00 PUT 100 46
31 Jan 16:20 19 Apr, 2024 15.00 CALL 223 374
31 Jan 16:20 19 Apr, 2024 15.00 PUT 223 64

About NovoCure Limited

NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.